Ignyta Inc., of San Diego, said preliminary results were presented from the ongoing phase I dose escalation portion of a phase I/II trial of RXDX-101, Ignyta’s oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.